Background There are limited data on immune responses to heterologous COVID-19
immunisation schedules, especially following an extended ≥12-week interval between doses. …

Define and identify long-term non-progressors (LTNP) and HIV controllers (HIC), and estimate
time until disease progression. LTNP are HIV-1 + patients who maintain stable CD4 + T-…

Complex mechanisms underlying the maintenance of fully functional, proliferative, HIV-1-specific
T-cell responses involve processes from early T-cell development through to the final …

Background HIV-1 + individuals who, without therapy, conserve cellular anti-HIV-1 responses,
present with high, stable CD4 + T-cell numbers, and control viral replication, facilitate …

Maraviroc (MVC) is the first licensed antiretroviral therapeutic agent to target a host cell
surface molecule, and successful HIV-1 entry blockade by this CC chemokine receptor type 5 (…

Background Efficacious immune-based therapy in treated chronic HIV-1 infection requires
the induction of virus-specific CD4 + T cells and subsequent maturation and maintenance of …

Objective. To review the epidemiology of coagulase-negative staphylococci (CoNS) in
England over the recent 12 year period. Methods. Laboratory-confirmed CoNS reported from …

Background Ineffective induction of T cell mediated immunity in older individuals remains a
persistent challenge for vaccine development. Thus, there is a need for more efficient and …

Exploring the intricacies of CD8 + T-cell epitope recognition using emerging technologies to
combine assessment of affinity, phenotype and resulting polyfunctional efficacy advances …

HIV-1 controllers (HIC) are extremely rare patients with the ability to control viral replication,
maintain unchanging CD4 T-cell count, and evade disease progression for extensive …